{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["table 3"],"not_rendered":{"external_links":1},"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"table 3","index":0,"n_rows":47,"n_cols":4,"rows_kept":47,"merged":[[0,0,0,3],[4,3,5,3],[7,3,8,3],[10,3,12,3],[14,3,15,3],[17,3,18,3],[20,3,21,3],[23,3,24,3],[26,3,27,3],[29,3,30,3],[32,3,33,3],[35,3,36,3],[38,3,39,3],[41,3,42,3]],"flags":["formulas_cached_only"]}
["Table 3. Evaluation of parameters associated with adverse events in CART therapy"]
[]
["paremeters","witn AE","without AE","p-value"]
["Age (n=233)"]
["≤60 years",12,110,{"v":1,"d":"1.000"}]
["≥61 years",10,101]
["Sex (n=233)"]
["male",16,147,{"v":1,"d":"1.000"}]
["female",6,64]
["Appearance of havested ascites (n=233)"]
["bloody",4,41,{"v":0.39,"d":"0.390"}]
["chylous",0,20]
["serous",18,150]
["Classificarion of havested ascites (n=233)"]
["exudative ascites",16,126,0.261]
["transudative ascites",6,85]
["Volume of havested ascites (n=233)"]
["≤4,720 mL ",7,110,0.051]
["≥4,721 mL",15,101]
["Volume of concentrated ascites (n=233)"]
["≤490 mL",8,110,0.183]
["≥491 mL",14,101]
["Processing rate of ascites (n=233)"]
["≤89 mL/min",14,105,0.265]
["≥90 mL/min",8,106]
["Volume of saline used for washing filter membrane (n=225)"]
["≤450 mL ",8,107,{"v":0.25,"d":"0.250"}]
["≥451mL",13,97]
["amount of calculated total protein for infusion (n=233)"]
["≤64.0 g",7,110,0.051]
["≥64.1 g",15,101]
["amount of calculated albumin for infusion (n=233)"]
["≤32.6 g ",7,111,{"v":0.0748,"d":"0.075"}]
["≥32.7 g",15,100]
["prophylaxis for AE (n=233)"]
["steroids †",20,180,0.748]
["other than steroids ‡",2,31]
["administration rate (n=228)"]
["≤100 mL/h",10,181,"< 0.001"]
["≥101 mL/h",12,25]
["administration rate in cases treated with steroids (n=196)"]
["≤100 mL/h",10,156,"< 0.001"]
["101 mL/h",10,20]
[]
["AE, adverse effects"]
["† equivalent to 100mg hydrocortisone or more "]
["‡ non-steroidal anti-Inflammatory drugs, antihistamines, etc."]